ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

Fadlo Khuri Named Editor-in-Chief Of ACS Journal Cancer

August 12, 2011

DCE Advisors approver New Grant Programs In Ovarian Cancer, Biostatistics, Biotech Transfer; Support Services Recompetitions

June 19, 1992

Mail Mixup Delays July 23 Issue

August 6, 1976

FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated

November 28, 1975

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

PNIH Says New Env. Care Study Section On The Way

February 3, 1978